Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > EY sees bolt-ons in the single to double digit billions now

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 21, 2022 6:47pm

171 Views

Post# 34977752

RE:EY sees bolt-ons in the single to double digit billions now

The spate of recent merger-and-acquisition deals is expected to grow in number and combined value during the second half of this year, according to EY’s Global Life Sciences Deals Leader Subin Baral

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario